Congratulations ! Xantho Bio’s New Drug Nominated for Edison Award, Highlighting Innovation and Strength
The Edison Award is regarded as the "Oscar" in the fields of innovation and business, recognizing the most groundbreaking products and technologies worldwide. Xantho Bio is committed to developing treatments for chronic inflammatory skin diseases using botanical ingredients.
GM-XANTHO successfully achieved the clinical trial enrollment milestone in January 2025!
Xantho Bio successfully completed the "A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GMXANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients" clinical trial enrollment (Last Subject Out, LSO) milestone in January 2025 !
Xantho Bio. presented in The 50th Annual Meeting of Taiwanese Dermatological Association
Xantho Bio. participated in the 50th Annual Meeting of the Taiwanese Dermatological Association (TDA), held on November 15-17, 2024, at the Taipei International Convention Center.
Xantho Bio. participated and presented in NPIC 2024 International Symposium on Natural Product Innovation and Commercialization
Xantho Bio. participated and presented in NPIC 2024 International Symposium on Natural Product Innovation and Commercialization
Xantho Biotechnology attended Bio Japan 2024 for global business partnering
The CEO and BD manager of Xantho Bio. attended Bio Japan 2024, one of the largest Bio convention in Asia, held in PACIFICO Yokohama Convention Center, Japan (from October 9 to October 11). During the 3-day event, Xantho Bio. participated in the one-on-one partnering meetings with international pharmaceutical companies to discuss drug licensing opportunities.
Xantho Bio. presented in the 39th Natural Products Symposium
Xantho Bio. participated in the 39th Natural Products Symposium and the 24th Society for Free Radical Research-Taiwan Symposium, co-hosted by National Taiwan University and Chang Gung University of Science and Technology, held from October 4th to 6th this year for three days of academic activities.
Attended BIO 2024 for global business partnering
Xantho Bio.participated in the BIO2024 in San Diego US, from June 3 to June 6, 2024, as part of the Taiwan delegation.
GM-XANTHO Phase 2a Clinical Progress
GM-XANTHO Phase 2a Clinical Progress Has Reached 80%.
Congrats! Taiwan invention patents have been granted for GM-XAN005 and GM-XAN006 in September 2023
Taiwan invention patents have been granted respectively for drug GM-XAN005 in the diabetic wound indication and for drug GM-XAN006 in the burn wound indication in September 2023.
Congrats! India Patent has been granted
Patent of GM-XANTHO has been granted by Directorate General of Intellectual Property(DGIP) in India in Apr 2023.